文献速递泌尿男性生殖肿瘤

BIND-014(靶向前列腺特异性膜抗原的多西他赛纳米颗粒)治疗转移性去势抵抗性前列腺癌的安全性与疗效:2期临床试验

Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.
PubMed 文献 · JAMA Oncol · 2018-01-01

该多中心开放标签2期试验纳入42例经阿比特龙和/或恩扎卢胺治疗后进展的化疗初治mCRPC患者,给予BIND-014 60 mg/m2联合泼尼松。结果显示PSA应答率30%,可测量病灶应答率32%,CTC转换率50%,中位影像学无进展生存期9.9个月,治疗相关不良事件主要为1-2级疲劳、恶心和神经病变。

要点

  • BIND-014在化疗初治mCRPC中显示抗肿瘤活性,PSA应答率30%,中位rPFS 9.9个月。
  • 治疗总体耐受良好,常见不良事件为1-2级疲劳、恶心和神经病变。
  • 基线PSMA阳性CTC在治疗后优先减少,或可用于筛选获益患者。

核心结论

  • BIND-014在化疗初治的mCRPC患者中具有活性且耐受良好。
  • 抗肿瘤活性可能与CTC上PSMA表达水平相关,提示治疗前可识别可能获益的患者。

研究设计与样本

  • 多中心开放标签2期临床试验,纳入42例经阿比特龙和/或恩扎卢胺治疗后进展的化疗初治mCRPC患者。
  • BIND-014 60 mg/m2静脉给药,每21天周期第1天,联合泼尼松,直至疾病进展或不可接受毒性。
  • 主要终点为根据PCWG2和RECIST 1.1的影像学无进展生存期。

主要发现

  • 40例可评估患者中12例(30%;95% CI,18%-45%)出现PSA应答(较基线降低≥50%)。
  • 19例可评估患者中6例(32%;95% CI,15%-54%)出现可测量疾病应答。
  • 26例可评估患者中13例(50%;95% CI,32%-68%)出现CTC转换(从≥5至<5个/7.5 mL血液)。
  • 中位影像学无进展生存期为9.9个月(95% CI,7.1-12.6)。
  • 18例中16例(89%)检测到CTC,11例(61%)基线PSMA阳性CTC高于分析阈值(范围0.4-72.4 CTCs/mL),治疗后PSMA阳性CTC优先减少。

关键数值与推荐

  • PSA应答定义为较基线降低≥50%。
  • CTC转换定义为CTC数量从≥5个/7.5 mL血液降至<5个/7.5 mL血液(CellSearch)。
  • 治疗相关不良事件包括1-2级疲劳(29/42,69%)、恶心(23/42,55%)、神经病变(14/42,33%)和中性粒细胞减少性发热(1/42,2%)。

临床怎么用

  • BIND-014可作为化疗初治mCRPC患者的一种治疗选择,但需进一步验证。
  • 治疗前检测CTC上PSMA表达可能有助于筛选潜在获益患者。
  • 治疗期间监测PSMA阳性CTC变化可能有助于评估疗效。

局限性

  • 为单臂2期试验,样本量较小(42例),无对照组。
  • PSMA表达与疗效的关系为探索性分析,需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Preferential delivery of docetaxel to tumors by prostate-specific membrane antigen (PSMA)-targeted nanoparticles is clinically effective, and the selective reduction of PSMA-positive circulating tumor cells (CTCs) after treatment has implications for patient selection and disease monitoring. OBJECTIVE: To determine the safety and efficacy of BIND-014, a PSMA-directed docetaxel-containing nanoparticle, in patients with metastatic castration-resistant prostate cancer (mCRPC). DESIGN, SETTING, AND PARTICIPANTS: A multicenter open-label, phase 2 clinical trial of 42 chemotherapy-naive patients with progressing mCRPC after treatment with abiraterone acetate and/or enzalutamide was conducted from June 24, 2013, to June 10, 2016. INTERVENTION: Treatment with BIND-014 at a dosage of 60 mg/m2 was given intravenously on day 1 of 21-day cycles in combination with prednisone until disease progression or unacceptable toxic effects occurred. MAIN OUTCOMES AND MEASURES: The primary end point was radiographic progression-free survival according to Prostate Cancer Working Group 2 recommendations and Response Evaluation Criteria in Solid Tumors, version 1.1. Secondary end points included prostate-specific antigen (PSA) response (≥50% reduction from baseline) and changes in CTC number (from ≥5 to <5 cells per 7.5 mL of blood) (CellSearch). Changes in CTC number based on PSMA expression levels on CTCs were also evaluated (Epic Sciences). RESULTS: Among the 42 patients (81% white), the median age was 66 (range, 50-85) years, and median number of doses received was 6 (range, 1-21). A PSA response was observed in 12 of 40 patients (30%; 95% CI, 18%-45%), measurable disease response in 6 of 19 (32% [95% CI, 15%-54%]), and CTC conversions in 13 of 26 (50%; 95% CI, 32%-68%). Median radiographic progression-free survival was 9.9 (95% CI, 7.1-12.6) months. With use of the Epic Sciences non-EPCAM-based CTC detection platform, CTCs were detected in 16 of 18 patients (89%); 11 of 18 (61%) had CTCs with PSMA expression above the analytical threshold level (PSMA positive) at baseline (range, 0.4-72.4 CTCs/mL). After treatment, PSMA-positive CTCs were preferentially reduced. Treatment-related adverse events included grade 1 or 2 fatigue (29 of 42 patients [69%]), nausea (23 [55%]), neuropathy (14 [33%]), and neutropenic fever (1 [2%]). CONCLUSIONS AND RELEVANCE: These findings suggest that treatment with BIND-014 is active and well tolerated in patients with chemotherapy-naive mCRPC. Antitumor activity may be related to PSMA expression levels on CTCs, which suggests that patients who are likely to benefit from this treatment can be identified before treatment is initiated. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01812746.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Autio KA, Dreicer R, Anderson J, et al. Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2018. PMID: 29978216. doi:10.1001/jamaoncol.2018.2168

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。